Background
Lung cancer, as one of the most common human malignancies, has been identified as the main cause of cancer-associated death in China and even across the world [
1,
2]. According to the categorization of lung cancer, it can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) on the basis of differentiated stages and morphological features [
3]. LUAD, which has been identified as the most dominant histological subclass of NSCLC, has high mortality as well as metastasis rate [
4‐
6]. In the past few years, great improvements have been made in the clinical treatment of LUAD, including anti-PD-1/PD-L1 therapy and molecule-targeted therapies [
7,
8]. Previous investigations have indicated that the initiation and progression of LUAD involves intricate biological processes that include plentiful genetic and epigenetic alterations [
9,
10]. Although multiple molecular genetic researches have been applied in LUAD, the specific molecular mechanisms concerning the progression of LUAD still needs to be further elaborated.
Long non-coding RNAs (lncRNAs), which are identified as a kind of transcripts with exceeding 200 nucleotides in length, have no capability of coding proteins [
11]. Aberrant expression of lncRNAs has been detected in a variety of human cancers, in which ovarian cancer [
12], colorectal cancer [
13] and LUAD [
14] are included. More importantly, dysregulation of lncRNAs has been manifested to be closely associated with the tumorigenesis and development of assorted human tumors. For example, MALAT1 knockdown facilitates the metastatic ability of cells in human breast cancer [
15]. Up-regulation of LOXL1-AS1 promotes cell proliferation and cell cycle by targeting miR-541-3p and CCND1 in prostate cancer [
16]. LINC01089 is a recently researched lncRNA and it has been uncovered to exert anti-tumor function in breast cancer [
17]. However, the possible regulatory mechanism and detailed function of LINC01089 in LUAD still need to be explored.
Through designing and conducting this study, we aimed to investigate the underlying regulatory role of LINC01089 in LUAD by implementing a series of functional assays and mechanism assays, which might provide a meaningful reference for LUAD treatment.
Methods
Cell lines and plasmid transfection
LUAD cell lines (PC9, H2073, H-1975, A549; ATCC, Manassas, VA, USA) and human bronchial epithelial cell line (BEAS-2B; ATCC) were cultivated in RPMI 1640 medium (Gibco, Grand Island, NY, USA) at 37 °C with 5% CO2. The penicillin, streptomycin and 10% fetal bovine serum (FBS; Gibco) were used as the medium supplements. PC9 cell line was purchased from Mingzhoubio (Ningbo, Zhejiang, China), and other cell lines were all bought from ATCC. The catalogue numbers of the cell lines are listed as follows: PC9 (MZ-0668); H2073 (CRL-5918); H-1975 (CRL-5908); A549 (CCL-185); BEAS-2B (CRL-9609).
For transfection, A549 and H-1975 cells at 80–90% confluence were seeded into 6-well plates and transfected for 48 h by using Lipofectamine 3000 kit (Invitrogen, Carlsbad, CA, USA). Cells stably transfection were screened by utilizing G418 and then applied in subsequent experiments. The pcDNA3.1/LINC01089, pcDNA3.1/STARD13 and control (pcDNA3.1), STARD13-specific shRNAs (sh-STARD13#1/2) and control (sh-NC), together with miR-301b-3p mimics/inhibitor and control (NC mimics/inhibitor), were all procured from RiboBio (Guangzhou, China). In addition, the primary ADC cells were used for in vivo assays with HLC as a control in the study. The sequences were listed as follows:
-
sh-NC: 5′-CCGGTTCTTTAAAAAAAAAATTTGTCTCGAGACAAATTTTTTTTTTAAAGAATTTTTG-3′,
-
sh-STARD13#1: 5′-CCGGGAGGGAAAAGGTCATCTTTCTCTCGAGAGAAAGATGACCTTTTCCCTCTTTTTG-3′,
-
sh-STARD13#2: 5′-CCGGCAGATTCATTAAGAGATGTTACTCGAGTAACATCTCTTAATGAATCTGTTTTTG-3′;
-
NC inhibitor: 5′-GCTTTGACAATATCATTTTTTTG-3′,
-
miR-301b-3p inhibitor: 5′-GCTTTGACAATATCATTGCACTG-3′;
-
NC mimics: 5′-GAGAAAGCAGUUCCUACGAUAUU-3′,
-
miR-301b-3p mimics: 5′-CAGUGCAAUGAUAUUGUCAAAGC-3′.
Real-time RT-qPCR (RT-qPCR)
In line with the manual of Trizol (Invitrogen), total RNA from A549 and H-1975 cells was obtained, centrifuged and washed. After using the Prime Script™ RT Master Mix (TaKaRa, Otsu, Japan), the synthesized cDNA was subjected to SYBR Green I fluorescent method (TaKaRa) on Applied Biosystems 7900 Real‐Time PCR System (Applied Biosystems, Foster City, CA, USA). The relative quantification of samples was tested by the equation 2
−ΔΔCt. GAPDH or U6 was used as the normalized control. The primer sequences were shown in Table
1.
Table 1
The sequences of primers used in RT-qPCR were presented
LINC01089 | Forward: 5′-GTGGAAGGAGCAGAACGTGA-3′ |
Reverse: 5′-CTTACTTACCCGCTCAGCCC-3′ |
STARD13 | Forward: 5′-CGAGGAGACAGAAATGGGTCA-3′ |
Reverse: 5′-TCCACTGCTTTCGCTGTGAAT-3′ |
miR-301b-3p | Forward: 5′-CAGTGCAATGATATTGTCAAAGC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-454-3p | Forward: 5′-TAGTGCAATATTGCTTATAGGGTGC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-301a-3p | Forward: 5′-CAGTGCAATAGTATTGTCAAAGCG-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-130b-3p | Forward: 5′-CAGTGCAATGATGAAAGGGC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-130a-3p | Forward: 5′-CAGTGCAATGTTAAAAGGGCAT-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-3666 | Forward: 5′-CAGTGCAAGTGTAGATGCCG-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-4295 | Forward: 5′-CAGTGCAATGTTTTCCTTGGA-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-148b-3p | Forward: 5′-TCAGTGCATCACAGAACTTTGTG-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-152-3p | Forward: 5′-TCAGTGCATGACAGAACTTGG-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-148a-3p | Forward: 5′-TCAGTGCACTACAGAACTTTGTCC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-27b-3p | Forward: 5′-TTCACAGTGGCTAAGTTCTGCC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-27a-3p | Forward: 5′-TTCACAGTGGCTAGTTCCGC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-370-5p | Forward: 5′-CAGGTCACGTCTCTGCAGTTAC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
miR-665 | Forward: 5′-ACCAGGAGGCTGAGCCC-3′ |
Reverse: 5′-CTCTACAGCTATATTGCCAGCCAC-3′ |
GAPDH | Forward: 5′-ACAACTTTGGTATCGTGGAAGG-3′ |
Reverse: 5′-GCCATCACGCCACAGTTTC-3′ |
U6 | Forward: 5′-ACGACAAACCTGCTGGTAGC-3′ |
Reverse: 5′-TCTGGACGAAGAGGATTCGC-3′ |
Cell counting kit-8 (CCK-8) assay
10 μl of CCK-8 reagents (Dojindo Molecular Technologies, Tokyo, Japan) was added to the medium containing A549 and H-1975 cells for 2 h. The microplate reader (Bio-Tek, Winooski, VT, USA) was applied for monitoring the absorbance at wavelength of 450 nm.
EdU incorporation assay
Cell proliferation of A549 and H-1975 was analyzed via EdU incorporation assay kit (Ribobio). LUAD cells were placed in 96-well plates with 100 μl of 50 μM EdU for 3 h, and then treated with 4% paraformaldehyde and 100 μl of 0.5% Troxin X-100 (×100; Sigma-Aldrich, Miamisburg, OH, USA). Following Apollo® 488 fluorescent staining, nuclei were counterstained with DAPI (Beyotime, Shanghai, China). Thereafter, cells were observed and analyzed with fluorescent microscope (Leica, Wetzlar, Germany).
Flow cytometry of apoptosis
Cell apoptosis of LUAD cells were measured with the help of FITC Annexin V Apoptosis Kit (BD Biosciences, San Jose, CA, USA). A549 and H-1975 cells treated with trypsin were washed in pre-cooled phosphate buffer saline (PBS). 5 × 105 cells were cultured in 100 μl of 1× binding buffer adding 5 μl of PI and 5 μl of FITC Annexin V at room temperature. After 400 μl of 1× binding buffer was added, Flow Cytometer (BD Biosciences) was utilized to determine cell apoptosis rate.
Wound healing assay
In the wound healing assay, the collected 5 × 105 A549 or H-1975 cells seeded in 24-well plates were cultivated at 37 °C until cells reached 100% confluence after transfection. Thereafter, cells were scraped by 200 μl sterile micropipette tip, and then cultured at 37 °C for 24 h. After being washed for three times in serum-free medium to clear the detached cells, the scratch was imaged by microscope at the time 0 h and 24 h for analysis.
Transwell assay for cell migration
This assay was conducted in 24-well Transwell chamber (Corning, Corning, NY, USA) containing 8 μm pore size polycarbonate membrane filter. A549 or H-1975 cells were seeded in the upper chamber with 500 μl of culture medium without FBS, while lower chamber was filled with 500 μl of complete medium. After 24 h of incubation, cells in the lower side were subjected to 4% formaldehyde (Sigma-Aldrich) and 1% crystal violet (Sigma-Aldrich), and then counted under optical microscope (Olympus, Tokyo, Japan) at ×200 magnification.
Subcellular fractionation assay
The segmentation of nucleus and cytoplasm was performed by PARIS™ kit (Ambion, Austin, TX, USA). 1 × 107 A549 or H-1975 cells were washed on ice and re-suspended in 500 μl pre-cooled cell fractionation buffer for 10 min. The supernatant was reaped as cell cytoplasm after centrifugation, while the nuclear deposit was treated with cell disruption buffer. After collecting nuclear and cytoplasmic fraction, RT-qPCR was performed for quantifying LINC01089, with GADPH and U6 as cytoplasmic and nuclear controls, respectively.
RNA pull-down assay
Using Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific, Waltham, MA, USA), RNA pull-down assay was carried out in A549 and H-1975 cells. Biotinylated LINC01089 probes (LINC01089 biotin probe) were incubated with cell extracts and streptavidin magnetic beads (Invitrogen). The LINC01089 no-biotin probe was used as the control. Finally, the RNA complexes bound to beads were analyzed by RT-qPCR.
Dual-luciferase reporter analysis
The pmirGLO luciferase vectors (Promega, Madison, WI, USA) containing the firefly reporter gene were formed using the wild-type (WT) or mutant (Mut) LINC01089 sequences with or without miR-301b-3p binding sites, termed as LINC01089-WT/Mut. A549 and H-1975 cells were plated to 24-well plates (5 × 104 cells/well), then co-transfected with LINC01089-WT/Mut for 48 h. Renilla luciferase reporter pRLCMV (Promega) acted as the normalized control. Dual-luciferase Reporter assay system (Promega) was applied to estimate the luciferase activity of each group.
Western blot
The lysed LUAD cells were separated on 10% SDS-PAGE and transferred electrophoretically onto PVDF membranes (Millipore, Billerica, MA, USA). Following the treatment with 5% non-fat milk (Merck KGaA, Darmstadt, Germany), membranes were cultivated with anti-STARD13 (1:2000 dilution; ab126489; Abcam, Cambridge, MA, USA) or anti-GAPDH (1:2000 dilution; ab128915; Abcam) primary antibodies all night, followed by incubation with HRP-labeled secondary antibody (1:2000 dilution; ab6728; Abcam). Finally, the membranes were exposed to ECL chemiluminescence Detection kit (Millipore). GAPDH was an internal control.
RNA immunoprecipitation (RIP)
Using Magna RIP RNA Binding Protein Immunoprecipitation Kit (Millipore), RIP assay was carried out in A549 and H-1975 cells using 5 μg anti-AGO2 (03-110; Millipore) or 5 μg anti-IgG antibodies (12-370; Millipore). Anti-IgG group served as a negative control, and cell lysates from RIP lysis buffer were treated with the beads conjugated with above antibodies for 2 h at 4 °C, followed by RNA analysis via RT-qPCR.
Statistical analysis
All data from experiments including three biological replications were exhibited as the mean ± standard deviation (SD). Data analysis was achieved by Student’s t-test (comparison for two groups) while one-way or two-way analysis of variance (ANOVA) applying GraphPad Prism 6.0 (GraphPad, San Diego, CA, USA) was utilized for evaluating the differences among multiple groups. Statistics results with p value below 0.05 were considered to be statistically significant.
Discussion
As the main subtype of NSCLC, LUAD is considered to be among the commonest malignant tumors with high death rate and metastasis rate [
4‐
6]. To improve LUAD therapies, researchers have been dedicated to studying the complicated cellular behaviors of LUAD progression in recent years. Chen et al. has clarified that dysregulation of lncRNAs in lung cancer are critical in regulating the biological processes of this cancer [
18]. Existing investigations have further manifested that lncRNAs play pivotal roles in regulating cell proliferation and metastasis in LUAD [
19,
20]. In addition, lncRNAs have been revealed to serve as a ceRNA by sponging miRNAs to regulate the expression of protein-coding genes and therefore exerting oncogenic or anti-tumor roles in different kinds of cancers, including LUAD [
16,
21]. According to previous studies, LINC01089 has been proved to be a newly confirmed anti-tumor lncRNA in breast cancer [
17]. Also, LINC01089 is found to be a lncRNA playing tumor-suppressive role in gastric cancer via regulating miR-27a-3p/TET1 axis [
22] and can block the proliferation as well as metastasis of colorectal cancer cells through the regulation of miR-27b-3p/HOXA10 axis [
23]. However, the role of LINC01089 in LUAD has not been studied yet. This research first explored the potential regulatory function of LINC01089 in LUAD progression. In this study, LINC01089 was discovered to be down-regulated in LUAD tissues and cells. Furthermore, LINC01089 overexpression repressed LUAD cell proliferation and migration ability while enhancing cell apoptosis.
Existing studies have suggested that lncRNAs may affect LUAD progression via the regulation of certain miRNAs [
21,
24]. In this study, owing to the fact that LINC01089 was found mainly in the cytoplasm of LUAD cells, we conjectured that LINC01089 might function as a ceRNA in LUAD by sponging miRNA to regulate the expression of target genes. Multiple reports have clarified that miR-301b-3p exerts the promoting influence on the progression of several human tumors, such as hepatocellular carcinoma [
25] and high-grade ovarian serous tumor [
26]. Through bioinformatics prediction and molecular mechanism assays, miR-301b-3p was confirmed to bind to LINC01089 in LUAD.
STARD13 has been reported to exert anti-tumor roles in various cancers which include prostate cancer [
27] and hepatocellular carcinoma [
28]. Besides, Li et al. have revealed the suppressive effect of STARD13-correlated ceRNA network on breast cancer metastasis [
29]. In current study, STARD13 was manifested to be directly targeted by miR-301b-3p in LUAD cells. Besides, it was demonstrated that LINC01089 could regulate STARD13 expression by sponging miR-301b-3p in LUAD. In addition, rescue assays revealed that decreased expression of STARD13 or increased expression of miR-301b-3p could offset the restraining effect caused by LINC01089 overexpression on LUAD progression.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.